RAMUCIRUMAB IN A COMBINATION WITH IRINOTECAN-BASED TWO-COMPONENT THERAPY REGIMEN AS THE SECOND LINE FOR THE TREATMENT OF DISSEMINATED GASTRIC CANCER. CASE REPORT
- 作者: Titova T.A1, Besova N.S1, Gorbunova V.A1, Fedenko A.A1, Malikhova O.A1
-
隶属关系:
- N.N. Blokhin National Medical Research Center of Oncology
- 期: 编号 7 (2018)
- 页面: 102-104
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295506
- ID: 295506
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
全文:
作者简介
T. Titova
N.N. Blokhin National Medical Research Center of OncologyMoscow
N. Besova
N.N. Blokhin National Medical Research Center of Oncology
Email: besovans@mail.ru
PhD in Medical Sciences, Senior Researcher at the Department of Chemotherapy Moscow
V. Gorbunova
N.N. Blokhin National Medical Research Center of OncologyMoscow
A. Fedenko
N.N. Blokhin National Medical Research Center of OncologyMoscow
O. Malikhova
N.N. Blokhin National Medical Research Center of OncologyMoscow
参考
- https://www.cancer.org/cancer/stomach-cancer/ 4. detection-diagnosis-staging/survival-rates.html
- Wilson D., Hiller L., Geh J.I. Review of second-line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005;17:81-90.
- Fuchs C.S., Tomasek J., Yong C.J., Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31-39. PMID: 24094768. doi: 10.1016/S0140-6736(13) 61719-5].
- Wilke H., Muro K., Van Cutsem E., et al.; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): a doubleblind, randomised phase 3 trial. Lancet Oncol. 2014;15:1224-35. PMID: 25240821. doi: 10.1016/S1470-2045(14) 70420-6]
- Yang L., Jiang X., Yan H., et al. Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer. BMC Gastroenterol. 2018;18:43. PMID: 29609559. doi: 10.1186/s12876-018-0772-4.
- Tabernero J., Yoshino T., Cohn A.L., et al. RAISE Study Investigators. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499-508. PMID: 25877855. doi: 10.1016/S1470-2045(15)70127-0.
补充文件
